Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France

详细信息    查看全文

• 作者：Sonia Zouaoui (1)
  Amélie Darlix (2)
  Pascale Fabbro-Peray (3)
  Hélène Mathieu-Daudé (4)
  Valérie Rigau (5)
  Michel Fabbro (2) (6)
  Faiza Bessaoud (4)
  Luc Taillandier (7)
  Fran?ois Ducray (8)
  Fabienne Bauchet (4)
  Michel Wager (9)
  Thierry Faillot (10)
  Laurent Capelle (11)
  Hugues Loiseau (12)
  Christine Kerr (2) (6)
  Philippe Menei (13)
  Hugues Duffau (1)
  Dominique Figarella-Branger (14)
  Olivier Chinot (15)
  Brigitte Trétarre (4)
  Luc Bauchet (1)
  
• 关键词：Database ; Elderly ; Glioblastoma ; Neurooncology ; Neurosurgery
• 刊名：Neurosurgical Review
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：37
• 期：3
• 页码：415-424
• 全文大小：
• 参考文献：1. Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, Iwamoto FM (2012) Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 109:391-97. doi:10.1007/s11060-012-0906-4 CrossRef
  2. Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 108:642-48. doi:10.3171/jns/2008/108/4/0642 CrossRef
  3. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Laine K, Schlama A, Thiebaut A, Patru MC, Bauchet F, Lionnet M, Wager M, Faillot T, Taillandier L, Figarella-Branger D, Capelle L, Loiseau H, Frappaz D, Campello C, Kerr C, Duffau H, Reme-Saumon M, Tretarre B, Daures JP, Henin D, Labrousse F, Menei P, Honnorat J (2010) Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12:725-35. doi:10.1093/neuonc/noq030 CrossRef
  4. Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, Moritz J, Puget S, Bauchet F, Pallusseau L, Duffau H, Coubes P, Trétarre B, Labrousse F, Dhellemmes P (2009) Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol 92:87-8. doi:10.1007/s11060-008-9740-0 CrossRef
  5. Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F (2007) French brain tumor data bank: Methodology and first results on 10,000 cases. J Neurooncol 84:189-99. doi:10.1007/s11060-007-9356-9 CrossRef
  6. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma. Cancer 115:3512-518. doi:10.1002/cncr.24406 CrossRef
  7. Central Brain Tumor Registry of the United States (CBTRUS) CBTRUS 2012 Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-008 http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf. Revised March 23, 2012. Accessed 06 Nov 2012
  8. Chargari C, Feuvret L, Bauduceau O, Ricard D, Cuenca X, Delattre J-Y, Mazeron J-J (2012) Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights. Cancer Treat Rev 38:988-95. doi:10.1016/j.ctrv.2011.12.010 CrossRef
  9. Davis FG, Malmer BS, Aldape K, Barnholtz-Sloan JS, Bondy ML, Br?nnstr?m T, Bruner JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, Wrensch MR, Buffler PA (2008) Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomark Prev 17:484-89. doi:10.1158/1055-9965.epi-07-0725 CrossRef
  10. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-009. Neuro Oncol 14(suppl 5):v1–v49. doi:10.1093/neuonc/nos218 CrossRef
  11. Gállego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29:3050-055. doi:10.1200/jco.2011.34.8086 CrossRef
  12. Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barceló I, Brell M, Pascual C, Crespo JA, Erro E, García-Romero JC, Estela J, Martino J, García-Casta?o A, Mata E, Lema M, Gelabert M, Fuentes R, Pérez P, Manzano A, Aguas J, Belenguer A, Simón A, Henríquez I, Murcia M, Vivanco R, Rojas-Marcos I, Mu?oz-Carmona D, Navas I, de Andrés P, Mas G, Gil M, Verger E (2013) Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-010 in Spain. Neuro Oncol [Epub ahead of print]
  13. Gulati S, Jakola AS, Johannesen TB, Solheim O (2012) Survival and Treatment Patterns of glioblastoma in the elderly: a population-based study. World Neurosurg 78:518-26. doi:10.1016/j.wneu.2011.12.008 CrossRef
  14. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-003. doi:10.1056/NEJMoa043331 CrossRef
  15. Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE (2009) Glioblastoma in the elderly. Cancer 115:3758-766. doi:10.1002/cncr.24413 CrossRef
  16. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma patients. Ann Neurol 64:628-34. doi:10.1002/ana.21521 CrossRef
  17. Johnson DR, O’Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359-64. doi:10.1007/s11060-011-0749-4 CrossRef
  18. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo J-S, Jadaud E, Colin P, Bondiau P-Y, Mene? P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron J-J, Bissery A, Delattre J-Y (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527-535. doi:10.1056/NEJMoa065901 CrossRef
  19. Kleihues P, Cavenee WK (2000) Tumours of the nervous system, pathology and genetics classification of tumours. International Agency for Research on Cancer Press, Lyon
  20. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, Weichselbaum RR, McCarthy BJ (2011) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107:207-12. doi:10.1007/s11060-011-0738-7 CrossRef
  21. Malmstr?m A, Gr?nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60?years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916-26. doi:10.1016/s1470-2045(12)70265-6 CrossRef
  22. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83:93-9. doi:10.1016/j.ijrobp.2011.06.1992 CrossRef
  23. Reardon DA (2012) Treatment of elderly patients with glioblastoma. Lancet Oncol 13:656-57. doi:10.1016/S1470-2045(12)70186-9 CrossRef
  24. Reyngold M, Lassman A, Chan T, Yamada Y, Gutin P, Beal K (2012) Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. J Neurooncol 110:369-74. doi:10.1007/s11060-012-0972-7 CrossRef
  25. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L (2011) French Brain Tumor DataBase: 5-Year histological results on 25 756 cases. Brain Pathol 21:633-44. doi:10.1111/j.1750-3639.2011.00491.x CrossRef
  26. R?nning PA, Helseth E, Meling TR, Johannesen TB (2012) A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol 14:1178-184. doi:10.1093/neuonc/nos153 CrossRef
  27. Scott J, Tsai Y-Y, Chinnaiyan P, Yu H-HM (2011) Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 81:206-10. doi:10.1016/j.ijrobp.2010.04.033 CrossRef
  28. Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM (2012) Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70?years or older. Cancer 118:5595-600. doi:10.1002/cncr.27570 CrossRef
  29. Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GHJ, Elinzano H, Chao ST (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70?years old or older: a retrospective review of 206 cases. Neuro Oncol 13:428-36. doi:10.1093/neuonc/nor005 CrossRef
  30. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-01. doi:10.1016/S1470-2045(06)70665-9 CrossRef
  31. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-96. doi:10.1056/NEJMoa043330 CrossRef
  32. Vuorinen V, Hinkka S, F?rkkil? M, J??skel?inen J (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 145:5-0. doi:10.1007/s00701-002-1030-6 CrossRef
  33. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, J??skel?inen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79-8, 10.1215/S1522-8517-02-00023-6
  34. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOASGotN-oWGotGCS (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-15. doi:10.1016/s1470-2045(12)70164-x CrossRef
  35. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-99. doi:10.1093/neuonc/4.4.278
  36. Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M, Figarella-Branger D, Taillandier L, Duffau H, Trétarre B, Bauchet L (2012) Recensement national histologique des tumeurs primitives du système nerveux central : résultats généraux sur 40 000 cas, principales applications actuelles et perspectives. Neurochirurgie 58:4-3. doi:10.1016/j.neuchi.2012.01.004 CrossRef
  
• 作者单位：Sonia Zouaoui (1)
  Amélie Darlix (2)
  Pascale Fabbro-Peray (3)
  Hélène Mathieu-Daudé (4)
  Valérie Rigau (5)
  Michel Fabbro (2) (6)
  Faiza Bessaoud (4)
  Luc Taillandier (7)
  Fran?ois Ducray (8)
  Fabienne Bauchet (4)
  Michel Wager (9)
  Thierry Faillot (10)
  Laurent Capelle (11)
  Hugues Loiseau (12)
  Christine Kerr (2) (6)
  Philippe Menei (13)
  Hugues Duffau (1)
  Dominique Figarella-Branger (14)
  Olivier Chinot (15)
  Brigitte Trétarre (4)
  Luc Bauchet (1)
  
  1. Department of Neurosurgery and INSERM U1051, H?pital Saint Eloi—Gui de Chauliac, Centre Hospitalier Universitaire, 80 avenue Augustin Fliche, 34 295, Montpellier cedex 5, France
  2. Department of Medical Oncology and Department of Radiation Oncology, ICM, Montpellier, France
  3. Department of Biostatistics, Institut Universitaire de Recherche Clinique, Montpellier, France and BESPIM, Centre Hospitalier Universitaire, N?mes, France
  4. Department of Epidemiology, Groupe de Neuro-Oncologie du Languedoc-Roussillon, Registre des Tumeurs de l’Hérault, ICM, Montpellier, France
  5. Department of Pathology, Centre Hospitalier Universitaire, H?pital Gui de Chauliac, Montpellier, France
  6. Department of Medical Oncology and Department of Radiation Oncology, Centre de Lutte Contre le Cancer Val d’Aurelle, Montpellier, France
  7. Neuro Oncology Unit, Department of Neurology, Centre Hospitalier Universitaire, Poitiers, France
  8. Department of Neuro-Oncology, H?pital Neurologique, Lyon, France
  9. Department of Neurosurgery, Centre Hospitalier Universitaire La Milétrie, Poitiers, France
  10. Department of Neurosurgery, AP-HP H?pital Beaujon, Clichy, France
  11. Department of Neurosurgery, AP-HP H?pital Pitié-Salpêtrière, Paris, France
  12. Department of Neurosurgery, Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
  13. Department of Neurosurgery, Centre Hospitalier Universitaire, Angers, France
  14. Department of Neuropathology and Inserm U 911, H?pital de la Timone, Université de la Méditerranée, Marseille, France
  15. Department of Neuro-Oncology, H?pital de la Timone, Université de la Méditerranée, Marseille, France
  
• ISSN：1437-2320

文摘

The incidence of glioblastoma (GBM) has increased in patients aged 70?years or older, and will continue to grow. Elderly GBM patients have been excluded from most clinical trials; furthermore, optimal care management as well as benefit/risk ratio of GBM treatments are still being debated. This study describes oncological patterns of care, prognostic factors, and survival for patients ?0?years in France. We identified patients over 70 with newly diagnosed and histologically confirmed GBM on data previously published by the French Brain Tumor DataBase. We included 265 patients. Neurological deficits and mental status disorders were the most frequent symptoms. The surgery consisted of resection (RS n--5) or biopsy (B n--70); 98 patients did not have subsequent oncological treatment. After surgery, first-line treatment consisted of radiotherapy (RT n--6), chemotherapy (CT n--2), and concomitant radiochemotherapy (CRC n--9). The median age at diagnosis was 76, 74, and 73?years, respectively, for the untreated, B-?RT and/or CT, RS?±?RT and/or CT groups. Median survival (in days, 95?% CI) with these main strategies, when analyzed according to surgical groups, was: B-CT n--1, 199[155-80]; B-CRC n--1, 318[166-80]; B-RT n--7, 149[130-14]; RS-CT n--1, 245[211–na]; RS-CRC n--8, 372[349-93]; RS-RT n--9, 269[218-43]. This population study for elderly GBM patients is one of the most important in Europe, and could be considered as a historical cohort to compare future treatments. Moreover, we can hypothesize that elderly patients (versus patients <70?years) are undertreated. Karnofsky performance status seems to be the most relevant clinical predictive factor, and RS and CRC have a positive impact on survival for elderly GBM patients in the general population, at least when feasible.